Crystallography News and Research

RSS

Single molecule FRET techniques combined with wavelet transforms give new view of AMPA receptor

A digital signal processing technique long used by statisticians to analyze data is helping Houston scientists understand the roots of memory and learning, Alzheimer's and Parkinson's diseases and stroke.

8 Feb 2011

Researchers develop hard X-ray laser to determine structure of biomolecules

Unraveling the molecular basis of life is an age-old quest of humanity. A breakthrough towards this goal was reported in a pair of studies published Feb. 3 in the scientific journal Nature, detailing a new method developed to determine structures of biomolecules based on diffraction from protein nanocrystals that are so small that they are not even visible under the microscope.

3 Feb 2011

Acetylation complex fits like a halo over a histone

To understand the emerging science of epigenetics-a field that describes how genes may be regulated without altering the underlying DNA itself-scientists are deciphering the many ways in which enzymes act on the proteins surrounding DNA within cells.

21 Jan 2011

Scientists determine protein structure that delivers genetic material of HIV to human cells

A team of scientists at The Scripps Research Institute and the University of Virginia has determined the structure of the protein package that delivers the genetic material of the human immunodeficiency virus to human cells.

19 Jan 2011

Zenobia, Lundbeck enter research collaboration for LRRK2 Parkinson's disease target

Zenobia Therapeutics, Inc. the leader in fragment-based lead discovery for CNS diseases, announced today a research collaboration with H. Lundbeck A/S utilizing Zenobia's expertise in protein expression and x-ray crystallography for the Parkinson's disease target, LRRK2. Under the agreement, Zenobia will continue to use its capabilities in fragment-based lead discovery (FBLD) to advance its internal LRRK2 drug discovery program independently of Lundbeck.

16 Dec 2010

Echo acoustic liquid handler improves discovery of potential therapeutics

When the revolutionary Echo® acoustic liquid handler is used in the process of discovering potential therapeutics, important drug candidates are identified that are missed using traditional liquid handlers. In a recently issued patent, the global pharmaceutical company AstraZeneca describes the discovery of a novel set of potential cancer therapeutics that was found only when the Echo system was used. Other major pharmaceutical companies have also reported that the Echo liquid handler was a critical platform in discovering drug candidates.

15 Dec 2010

Researchers decipher mechanism responsible for dental plaque sticking to teeth

The Groningen professors Bauke Dijkstra and Lubbert Dijkhuizen have deciphered the structure and functional mechanism of the glucansucrase enzyme that is responsible for dental plaque sticking to teeth. This knowledge will stimulate the identification of substances that inhibit the enzyme. Just add that substance to toothpaste, or even sweets, and caries will be a thing of the past. The results of the research have been published this week in the journal Proceedings of the National Academy of Sciences (PNAS).

4 Dec 2010

First-ever selective irreversible inhibition of viral protease using targeted covalent drug

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, has published research in Nature Chemical Biology demonstrating the first-ever selective irreversible inhibition of a viral protease using a targeted covalent drug.

30 Nov 2010

New irreversible covalent approach to inhibit viral protease

28 Nov 2010

Improving immune system to defend against HIV infection

Researchers have been stymied for years over the fact that people infected with the AIDS virus do indeed produce antibodies in response to the pathogen - antibodies that turn out to be ineffective in blocking infection.

19 Nov 2010

NovAliX enters agreement to acquire Graffinity

NovAliX SAS today announced that it has entered into a definitive agreement to acquire a majority interest in Graffinity Pharmaceuticals GmbH of Heidelberg, Germany, a leading fragment based drug discovery services company.

16 Nov 2010

MqsA and MqsR protein complex can disrupt drug-resistant biofilm formation

When a foreign object such as a catheter enters the body, bacteria may not only invade it but also organize into a slick coating - a biofilm - that is highly resistant to antibiotics. Like sophisticated organized crime rings, biofilms cannot be defeated by a basic approach of conventional means. Instead doctors and drug developers need sophisticated new intelligence that reveals the key players in the network and how they operate. New research led by biologists at Brown University provides exactly that dossier on some key proteins in the iconic bacterium E. coli.

11 Nov 2010

CR4354 antibody uses crosslinking mechanism to neutralize West Nile virus

Researchers have learned the structure that results when an antibody binds to the West Nile virus, neutralizing the virus by locking up its infection mechanism. The information could help scientists develop a vaccine against the mosquito-borne disease.

3 Nov 2010

Researchers reveal molecular structure of blood-clotting enzyme

Using state-of-the-art robotic and x-ray crystallographic equipment, researchers at Saint Louis University have revealed for the first time the molecular structure of the zymogen, or inactive, form of a blood-clotting enzyme.

3 Nov 2010

Scientists determine tertiary structure of TehA membrane protein in Haemophilus bacteria

Proteins are molecular machines that transport substances, catalyze chemical reactions, pump ions, and identify signaling substances. They are chains of amino acids and the individual amino acid sequence is known for many of them. However, the functions a protein can carry out inside the cell are determined by the three-dimensional spatial structure of the protein. Establishing this so-called tertiary structure presents a great challenge to scientists.

28 Oct 2010

BioSilta releases EnPresso tablet that regulates protein production in recombinant bacteria

BioSilta announces the release of the EnPresso Tablet Cultivation Set, a tabletised form of the patented EnBase technology. The EnBase technology is based on providing an enzymatic-controlled glucose supply in a fed-batch type manner, which allows an extended growth period and promotes higher final cell density.

27 Oct 2010

MU researchers examine Aspergillus fumigatus to find cure for fungus, parasite

If finding the cure for a fungus and parasite that affects millions of people were the subject of a detective show, University of Missouri Chemistry Professor John Tanner would be the forensic expert in the lab, using high-tech equipment to make a model that could eventually solve the crime.

20 Oct 2010

Biologists determine three-dimensional structure of molecule involved in HIV, cancer

In a technical tour de force, structural biologists funded by the National Institutes of Health have determined the three-dimensional structure of a molecule involved in HIV infection and in many forms of cancer. The high-resolution structure sheds light on how the molecule functions and could point to ways to control its activity, potentially locking out HIV and stalling cancer's spread.

8 Oct 2010

Bruker closes acquisition of instruments businesses with Veeco

Bruker Corporation today announced the closing of its acquisition of the Atomic Force Microscopy (AFM) and the Optical Industrial Metrology (OIM) instruments businesses from Veeco Instruments, Inc. for $229.4 million in cash.

8 Oct 2010

Evotec enters multiple target drug discovery collaboration with Shionogi

Evotec AG today announced that it has entered into a multiple target drug discovery collaboration with Shionogi & Co Ltd., to identify small molecule modulators of various protein-protein interaction targets.

5 Oct 2010